Simcyp’s Simulators allow in silico prediction of drug absorption, distribution, metabolism excretion (ADME) and potential drug-drug interactions.

The Consortium acts as a steering committee, guiding scientific research and development at Simcyp.

There is also close collaboration with regulatory bodies (the U.S. Food and Drug Administration, Swedish Medical Products Agency, NAM, ECVAM) and academic centres of excellence worldwide, within the framework of the Consortium.

The Simulator models drug absorption, distribution, metabolism and elimination using routinely generated in vitro data.

Human liver microsomes Human intestinal microsomes Human kidney microsomes Human hepatocytes Recombinant CYP and UGT enzymes Competitive enzyme inhibition Irreversible, mechanism (time)-based enzyme inhibition (including auto-inhibition)Enzyme-induction (including auto-induction)Multiple interactions (involving up to four drugs plus two metabolites) with complex study designs Gastric emptying rate and intestinal and colon transit times Regio- and age-specific luminal pH as it affects ionisation, solubility, chemical stability, permeability, dissolution and precipitation GI tract surface area and regional variation in permeability and enzyme and transporter density Luminal fluid volumes and dynamics Fed versus fasting states It allows evaluation of immediate and modified release formulations and the impact of particle size on dissolution rate